<DOC>
	<DOC>NCT00041652</DOC>
	<brief_summary>The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.</brief_summary>
	<brief_title>Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Disease Characteristics: Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma Measurable lesion diagnosed by CT scan Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment) Other: Prior treatment with investigational agents is excluded unless followup is completed and patient is off study Patient Characteristics/ Performance Status: Patients with a Karnofsky performance status &gt; 70% (or equivalent, ECOG 01) and expected survival of at least 3 months. Hematopoietic: WBC &gt;/= 3000 mm3, neutrophils &gt;/= 1500 mm3, platelets &gt;/= 75,000, CEA &lt; 300 ng/mL Hepatic: Serum bilirubin &lt;/= 2.0 mg/dL, ALT &lt; 2.5 x IULN Cardiovascular: Patients with LVEF &gt;/= 40% by required MUGA/2DECHO study. Pulmonary: Patients with FEV1 &gt;/= 60% by required Pulmonary Function Tests Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Neoplasms</keyword>
</DOC>